Cargando…

Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model

DNA-encoded delivery and in vivo expression of antibody therapeutics presents an innovative alternative to conventional protein production and administration, including for cancer treatment. To support clinical translation, we evaluated this approach in 18 40-45 kg sheep, using a clinical-matched in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hollevoet, Kevin, Thomas, Debby, Compernolle, Griet, Vermeire, Giles, De Smidt, Elien, De Vleeschauwer, Stéphanie, Smith, Trevor R. F., Fisher, Paul D., Dewilde, Maarten, Geukens, Nick, Declerck, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574358/
https://www.ncbi.nlm.nih.gov/pubmed/36263202
http://dx.doi.org/10.3389/fonc.2022.1017612
_version_ 1784811086621442048
author Hollevoet, Kevin
Thomas, Debby
Compernolle, Griet
Vermeire, Giles
De Smidt, Elien
De Vleeschauwer, Stéphanie
Smith, Trevor R. F.
Fisher, Paul D.
Dewilde, Maarten
Geukens, Nick
Declerck, Paul
author_facet Hollevoet, Kevin
Thomas, Debby
Compernolle, Griet
Vermeire, Giles
De Smidt, Elien
De Vleeschauwer, Stéphanie
Smith, Trevor R. F.
Fisher, Paul D.
Dewilde, Maarten
Geukens, Nick
Declerck, Paul
author_sort Hollevoet, Kevin
collection PubMed
description DNA-encoded delivery and in vivo expression of antibody therapeutics presents an innovative alternative to conventional protein production and administration, including for cancer treatment. To support clinical translation, we evaluated this approach in 18 40-45 kg sheep, using a clinical-matched intramuscular electroporation (IM EP) and hyaluronidase-plasmid DNA (pDNA) coformulation setup. Two cohorts of eight sheep received either 1 or 4 mg pDNA encoding an ovine anti-cancer embryonic antigen (CEA) monoclonal antibody (mAb; OVAC). Results showed a dose-response with average maximum serum concentrations of respectively 0.3 and 0.7 µg/ml OVAC, 4-6 weeks after IM EP. OVAC was detected in all 16 sheep throughout the 6-week follow-up, and no anti-OVAC antibodies were observed. Another, more exploratory, cohort of two sheep received a 12 mg pOVAC dose. Both animals displayed a similar dose-dependent mAb increase and expression profile in the first two weeks. However, in one animal, an anti-OVAC antibody response led to loss of mAb detection four weeks after IM EP. In the other animal, no anti-drug antibodies were observed. Serum OVAC concentrations peaked at 4.9 µg/ml 6 weeks after IM EP, after which levels gradually decreased but remained detectable around 0.2 to 0.3 µg/ml throughout a 13-month follow-up. In conclusion, using a delivery protocol that is currently employed in clinical Phase 1 studies of DNA-based antibodies, we achieved robust and prolonged in vivo production of anti-cancer DNA-encoded antibody therapeutics in sheep. The learnings from this large-animal model regarding the impact of pDNA dose and host immune response on the expressed mAb pharmacokinetics can contribute to advancing clinical translation.
format Online
Article
Text
id pubmed-9574358
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95743582022-10-18 Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model Hollevoet, Kevin Thomas, Debby Compernolle, Griet Vermeire, Giles De Smidt, Elien De Vleeschauwer, Stéphanie Smith, Trevor R. F. Fisher, Paul D. Dewilde, Maarten Geukens, Nick Declerck, Paul Front Oncol Oncology DNA-encoded delivery and in vivo expression of antibody therapeutics presents an innovative alternative to conventional protein production and administration, including for cancer treatment. To support clinical translation, we evaluated this approach in 18 40-45 kg sheep, using a clinical-matched intramuscular electroporation (IM EP) and hyaluronidase-plasmid DNA (pDNA) coformulation setup. Two cohorts of eight sheep received either 1 or 4 mg pDNA encoding an ovine anti-cancer embryonic antigen (CEA) monoclonal antibody (mAb; OVAC). Results showed a dose-response with average maximum serum concentrations of respectively 0.3 and 0.7 µg/ml OVAC, 4-6 weeks after IM EP. OVAC was detected in all 16 sheep throughout the 6-week follow-up, and no anti-OVAC antibodies were observed. Another, more exploratory, cohort of two sheep received a 12 mg pOVAC dose. Both animals displayed a similar dose-dependent mAb increase and expression profile in the first two weeks. However, in one animal, an anti-OVAC antibody response led to loss of mAb detection four weeks after IM EP. In the other animal, no anti-drug antibodies were observed. Serum OVAC concentrations peaked at 4.9 µg/ml 6 weeks after IM EP, after which levels gradually decreased but remained detectable around 0.2 to 0.3 µg/ml throughout a 13-month follow-up. In conclusion, using a delivery protocol that is currently employed in clinical Phase 1 studies of DNA-based antibodies, we achieved robust and prolonged in vivo production of anti-cancer DNA-encoded antibody therapeutics in sheep. The learnings from this large-animal model regarding the impact of pDNA dose and host immune response on the expressed mAb pharmacokinetics can contribute to advancing clinical translation. Frontiers Media S.A. 2022-10-03 /pmc/articles/PMC9574358/ /pubmed/36263202 http://dx.doi.org/10.3389/fonc.2022.1017612 Text en Copyright © 2022 Hollevoet, Thomas, Compernolle, Vermeire, De Smidt, De Vleeschauwer, Smith, Fisher, Dewilde, Geukens and Declerck https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Hollevoet, Kevin
Thomas, Debby
Compernolle, Griet
Vermeire, Giles
De Smidt, Elien
De Vleeschauwer, Stéphanie
Smith, Trevor R. F.
Fisher, Paul D.
Dewilde, Maarten
Geukens, Nick
Declerck, Paul
Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model
title Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model
title_full Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model
title_fullStr Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model
title_full_unstemmed Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model
title_short Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model
title_sort clinically relevant dosing and pharmacokinetics of dna-encoded antibody therapeutics in a sheep model
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574358/
https://www.ncbi.nlm.nih.gov/pubmed/36263202
http://dx.doi.org/10.3389/fonc.2022.1017612
work_keys_str_mv AT hollevoetkevin clinicallyrelevantdosingandpharmacokineticsofdnaencodedantibodytherapeuticsinasheepmodel
AT thomasdebby clinicallyrelevantdosingandpharmacokineticsofdnaencodedantibodytherapeuticsinasheepmodel
AT compernollegriet clinicallyrelevantdosingandpharmacokineticsofdnaencodedantibodytherapeuticsinasheepmodel
AT vermeiregiles clinicallyrelevantdosingandpharmacokineticsofdnaencodedantibodytherapeuticsinasheepmodel
AT desmidtelien clinicallyrelevantdosingandpharmacokineticsofdnaencodedantibodytherapeuticsinasheepmodel
AT devleeschauwerstephanie clinicallyrelevantdosingandpharmacokineticsofdnaencodedantibodytherapeuticsinasheepmodel
AT smithtrevorrf clinicallyrelevantdosingandpharmacokineticsofdnaencodedantibodytherapeuticsinasheepmodel
AT fisherpauld clinicallyrelevantdosingandpharmacokineticsofdnaencodedantibodytherapeuticsinasheepmodel
AT dewildemaarten clinicallyrelevantdosingandpharmacokineticsofdnaencodedantibodytherapeuticsinasheepmodel
AT geukensnick clinicallyrelevantdosingandpharmacokineticsofdnaencodedantibodytherapeuticsinasheepmodel
AT declerckpaul clinicallyrelevantdosingandpharmacokineticsofdnaencodedantibodytherapeuticsinasheepmodel